Introduction
Hematopoietic stem cells have been extensively studied as potential targets for corrective gene transfer with retroviral vectors in inherited and acquired hematopoietic disorders. Retroviral transduction of the predominantly noncycling hematopoietic stem cells has been difficult to achieve due to the dependence on cell division for integration of retroviral vector DNA and the relatively low abundance of stem cells in primary cell preparations. [1] [2] [3] [4] Although currentlly used in vitro retroviral transduction procedures include the use of growth factors to stimulate cell cycling of early hematopoietic progenitor cells, the combination and concentration of growth factors required to achieve specific cycling and efficient transduction of repopulating stem cells is not known. Moreover, functional analysis of hematopoietic stem cells relies on determining the proliferation and differentiation potential of a relatively impure cell population in time-consuming in vitro cell culture or in vivo long-term repopulating assays which have further hampered systematic studies toward their in vitro expansion. Retroviral-mediated gene transfer into hematopoietic stem cells may be improved by targeting phenotypically defined immature cell populations, and by in vitro or in vivo manipulations that increase the number of hematopoietic stem cells and promote their cell cycling activity. The application of reporter molecules, such as the low-affinity nerve growth factor receptor (LNGFR), the human cell surface CD24 antigen and its murine homologue heat-stable antigen (HSA), allows for the rapid detection of transgene expression and selection of phenotypically defined immature hematopoietic cells. [5] [6] [7] [8] [9] [10] [11] Strategies based on these approaches may allow for the optimization of retroviral-mediated gene delivery procedures in hematopoietic stem cells and the use of relatively pure populations of transduced cells for functional analysis by long-term repopulating assays in animals.
The utility of mutated versions of the green fluorescent protein (enhanced GFP or EGFP), optimized for expression in mammalian cells and for detection by standard fluorescence microscopy and FACS, has also been examined as a marker of retroviral-mediated gene transfer. Although some retroviral vector/packaging systems may not be suited for the production of high titer EGFP retroviral vectors, 12 stable retroviral producer cell lines for GFP-encoding retroviral vectors have been reported and the potential of EGFP as a selectable reporter has been demonstrated in murine and human cell lines, [13] [14] [15] [16] as well as primary murine and human hemopoietic cells. [17] [18] [19] [20] A bright green fluorescence signal was easily detected in these cells which could be selected for by FACS, and functional analysis of the transduced cells revealed EGFP expression in in vitro clonogenic progenitors, murine spleen colony-forming cells (day-12 CFU-S), human cobble-stone area forming cells (CAFC), in peripheral blood cells and marrow repopulating cells of transplanted mice and in BM of immunodeficient mice transplanted with transduced human cord blood CD34 + cells. 19, 21, 22 In the present study we extend these findings by showing high levels of EGFP expression in CD34 + cells and immature subpopulations thereof in rhesus monkey and human BM. Since it can be envisaged that future clinical gene transfer protocols will be preferentially based on mobilized PB stem cells, we also examined the potential of generating highly purified populations of transduced rhesus monkey CD34 + EGFP-positive PB cells mobilized with FLT3 ligand (FL) and G-CSF, which should be useful for the study of their intrinsic functional properties in in vitro cell culture methods and in preclinical gene transfer models.
Materials and methods

Animals
Captive bred male rhesus monkeys (Macaca mulatta), weighing 2.5-4.0 kg and aged 2 to 3 years, were used. The monkeys were housed in groups of four to six in stainless steel cages in rooms equipped with reverse filtered air barrier, normal day light rhythm and conditioned to 20°C with a relative humidity of 70%. Animals were fed ad libitum with commercial primate chow, fresh fruits, and received acidified drinking water. All animals were free of intestinal parasites and seronegative for herpes B, simian T-lymphotropic viruses and simian immunodeficiency virus. Housing, experiments and all other conditions were approved by an ethical committee in conformity with legal regulations in The Netherlands.
Procurement and isolation of rhesus monkey and human CD34
+ progenitor cells
Rhesus monkey BM cells were obtained either freshly by BM aspiration or from frozen BM material of earlier aspirates. For mobilization of CD34 + cells, rhesus monkeys were treated with 100 g/kg human FL (Immunex, Seattle, WA, USA) and 100 g/kg human G-CSF (Amgen, Thousand Oaks, CA, USA) (s.c. administered) for either 8 or 14 consecutive days and blood was sampled on day 8 and day 15 of treatment. 23 Surplus cells of normal donor BM transplant harvests obtained with informed consent were used as source of human BM cells for this study. Low-density mononuclear cells were isolated from crude cell populations by Ficoll density gradient centrifugation (Nycomed Pharma, Oslo, Norway) and enriched for CD34
+ cells using an IgG2A antibody against CD34 (MoAb 561) that was noncovalently linked to rat antimouse IgG2A-conjugated beads (Dynabeads; Dynal, Oslo, Norway) as described. 24 
Culture of cells
The human hematopoietic cell line KG1A was cultured in an enriched version of Dulbecco's modified Eagle's medium (DMEM; GIBCO, Gaithersburg, MD, USA) supplemented with 10% (v/v) fetal calf serum (FCS). The adjustment of the DMEM used for this study included the addition of L-alanine (25 mg/l), L-asparagine (50 mg/l), L-aspartic acid (30 mg/l), L-cysteine (70 mg/l), L-glutamic acid (75 mg/l), L-proline (40 mg/l), sodium pyruvate (110 mg/l), vitamin B 12 (25 g/l), and biotin (30 g/l) (all from Sigma, St Louis, MO, USA). Rhesus monkey and human BM cells were cultured in this enriched DMEM further supplemented with 1.5% (w/v) BSA (Fraction V; Sigma), 0.23 mg/ml human transferrin, 0.1 mol/l sodium selenite, 1 mg/l nucleosides (cytidine, adenosine, uridine, guanosine, 2Ј-deoxycytidine, 2Ј-deoxyadenosine, thymidine and 2Ј-deoxyguanosine; Sigma), 0.1 mmol/l ␤-mercaptoethanol, 15 mol/l linoleic acid, 15 mol/l cholesterol, 10 mg/ml insulin and 5% (v/v) FCS. The amphotropic packaging cell line GP + envAm12 25 and retroviral producer aMFG-EGFP 20 were cultured in DMEM supplemented with 10% (v/v) newborn calf serum (NBCS). Media for all cultures routinely included 100 units/ml of penicillin and 100 g/ml of streptomycin. The cultures were maintained at 37°C with 10% CO 2 /90% air in a humidified atmosphere. The amphotropic retroviral producer aMFG-EGFP used for this study stably produced approximately 10 6 infectious particles per milliliter of conditioned supernatant free of replication-competent virus, as verified by failure to transfer EGFP expression from transduced to nontransduced NIH 3T3 fibroblasts. 20 
Retroviral transduction of cell lines and BM cells
KG1A cells were cultured for 2 days at a starting density of 2 × 10 5 cells per ml on an irradiated (20 Gy, 137 Cs ␥-rays) monolayer of GP + envAm12 packaging (as control) or aMFG-EGFP producer cells in their appropriate culture medium supplemented with hexadimethrine bromide (4 g/ml; Sigma). Subsequently, the non-adherent and loosely adherent cells were recovered by gentle pipetting and culture was continued for at least 1 day before flow cytometric analysis. Gene transfer into primary rhesus monkey and human hematopoietic cells was established by a fibronectin-mediated retroviral supernatant procedure as described previously. [26] [27] [28] Briefly, Falcon 1008 (35-mm) bacteriological culture dishes were coated with retronectin (recombinant fibronectin fragment CH-296; Boehringer Ingelheim, Belgium) at a concentration of approximately 10 g/cm 2 as prescribed by the manufacturer. Rhesus monkey and human CD34 + cells were prestimulated for 2 days in their appropriate culture medium, as mentioned above, supplemented with 10 ng/ml human interleukin-6 (hIL-6; Ares-Serono, Geneva, Switzerland), 30 ng/ml rhesus monkey (rhIL-3) 29, 30 or human interleukin-3 (hIL-3), 31 ,32 respectively, and 100 ng/ml human stem cell factor (hSCF; Immunex, Seattle, WA) at a starting cell concentration of 1 to 5 × 10 5 nucleated cells/ml. Control or retroviral vector-containing supernatants were obtained by harvesting target cell culture medium of 80-100% confluent overnight cultures of GP + envAm12 packaging or aMFG-EGFP producer cells, respectively, and passing them through a 0.45 m filter. Before adding the CD34 + cells to the retronectin-coated dishes, dishes were pre-loaded with control or retroviral supernatant (based on target cell culture medium, 2 ml per dish) for 1 h at 37°C. Subsequently, nucleated cells were resuspended at 2 to 10 × 10 5 /ml (2 ml per dish) in the corresponding supernatants supplemented with IL-6, IL-3, and SCF as mentioned above, and added to the dishes. Over a total period of 48 h the retroviral supernatant was changed an additional two times, each time resuspending non-adherent cells into fresh supernatant. Finally, the cells were harvested and used for FACS analysis/sorting and in vitro clonogenic progenitor assays.
Flow cytometry
Dependent on the type of experiment, cells were analyzed or selected using a FACScan flow cytometer, a FACSCalibur or a FACS Vantage cell sorter (Becton Dickinson, San Jose, CA, USA). Dead cells were excluded from analysis based on propidium iodide (Sigma) or Hoechst 33258 (Molecular Probes, Eugene, OR, USA) staining. The Cyanine-5 bisfunctional reactive dye (Amersham Life Science, Pitsburgh, PA, USA) was conjugated to the CD34-specific monoclonal antibody 566 according to the manufacturer's directions and the resulting anti-CD34-Cy5 conjugate was used to characterize EGFP-and mock-transduced human and rhesus monkey cells. In some experiments the presence of the CD34 antigen was visualized in a two-step staining procedure using first the CD34-specific monoclonal antibody 566 followed by incubation with goat 
In vitro clonogenic progenitor assays
BM cells were plated at appropriate numbers in Falcon 1008 (35-mm) bacteriological culture dishes in 1 ml of semisolid methylcellulose culture medium containing 0.8% (w/v) methylcellulose (Methocel A4M Premium grade; Dow Chemical, Barendrecht, The Netherlands) in enriched DMEM, 1.5% (w/v) BSA, 0.23 mg/ml human transferrin, 0.1 mol/l sodium selenite, 1 mg/l nucleosides (as above), 0.1 mmol/l ␤-mercaptoethanol, 15 mol/l linoleic acid, 15 mol/l cholesterol, 10 mg/ml insulin, 5% FCS, 100 U/ml penicillin and 100 g/ml streptomycin. Granulocyte/macrophage colony formation (GM-CFU) was stimulated by 10 ng/ml human GM-CSF (hGM-CSF; Behringwerke AG, Marburg, Germany), 100 ng/ml of hSCF, and either 30 ng/ml of rhIL-3 or hIL-3. Burst-forming units-erythroid (BFU-E) growth was induced by 100 ng/ml hSCF and 4 U/ml human erythropoietin (hEPO; Behringwerke AG) in the presence of 2 × 10 −4 mol/l hemin (bovine, type I; Sigma). GM-CFUs and BFU-Es were scored at days 8 to 12 of culture, studied either by inverted fluorescence microscopy or individually isolated and analyzed by FACS or PCR as described. 20 All cultures were grown in duplicate and maintained at 37°C with 10% CO 2 /90% air in a humidified atmosphere.
Results
Transduction and selection of human KG1A cells
In the retroviral vector used for this study (MFG-EGFP), EGFP expression is transcriptionally controlled by the Moloney murine leukemia virus (MoMLV) long terminal repeat (LTR). The corresponding amphotropic retroviral producer, aMFG-EGFP, stably expresses EGFP and produces recombinant retrovirus at an estimated viral titer of 10 6 infectious particles/ml supernatant. This retroviral vector has been used to transduce murine hematopoietic progenitor cells at high efficiency. 20 To further evaluate the potential of EGFP expression from this retroviral vector as a marker for gene transfer in human hematopoietic cells, KG1A cells were transduced by cocultivating them for 2 days with aMFG-EGFP cells. Flow cytometric analysis of the cells 24 h after recovery from the producers revealed that approximately 50% of the cells (Figure 1a , upper left panel) displayed a bright green fluorescent signal. The effect of EGFP expression on cell growth was examined by determining the cell numbers at weekly intervals and FACS profiles every 2 weeks of both mock-and EGFP-transduced KG1A cells. As is shown in Figure 1a (lower left panel), over a period of approximately 1 month differences in growth characteristics could not be detected between the control and EGFP-expressing cells; despite 16 cell doublings the percentage of EGFP-positive cells was not essentially reduced during this period (Figure 1b ). These results demonstrate that EGFP expression is stable during in vitro cell culture and has no significant effect on the growth of KG1A cells, which is in accordance with our earlier findings for primary murine BM progenitor cells. 20 Since KG1A cells are known to express the CD34 antigen 33 we tested the feasibility for selecting CD34 + KG1A cells on the basis of EGFP expression. Almost pure and viable populations of CD34 + EGFP-negative and CD34 + EGFPpositive KG1A cells could be readily obtained from the total transduced cell population using the FL4 emission channel of the FACSCalibur for detection of the CD34 antigen (CD34-Cy5) and the FL1 emission channel for green fluorescence detection (Figure 1a , right panels). The detection of CD34 expression in conjunction with EGFP expression was not restricted to the FL4 emission channel alone: anti-CD34 antibodies conjugated to, eg peridinin chlorophyll protein (PerCP; FL3 emission channel) or phycoerythrin (PE; FL2 emission channel) were successfully used as well (results not shown), which demonstrates the potential to determine transduction efficiencies with EGFP in viable hematopoietic cell populations defined by two or even three phenotypic markers.
Transduction and selection of rhesus and human hematopoietic progenitor cells
Rhesus monkey and human BM cells were enriched for CD34 expression by an immunomagnetic bead selection method (up to 90% CD34 + as determined by flow cytometry with anti-CD34-Cy5), prestimulated for 2 days with IL-3, IL-6 and SCF, and subsequently transduced with the aMFG-EGFP retroviral vector. For rhesus monkey BM cells a transduction efficiency between 11 and 35% of the total cell population (seven independent experiments, Figure 1b and c, upper panels). When these cells were FACS-selected on the basis of CD34 and EGFP expression, enriched populations (у87% pure) of CD34 + EGFP-negative and CD34 + EGFP-positive cells were obtained (Figure 1b and c, lower panels) . These results clearly demonstrate the feasibility of using EGFP expression as a selectable marker to obtain relatively pure populations of viable and retrovirally transduced CD34
+ rhesus monkey and human BM cells.
Total mock-transduced, EGFP-transduced, CD34 + EGFPnegative and CD34
+ EGFP-positive rhesus monkey and human BM cells were used for in vitro clonogenic progenitor assays (GM-CFU, BFU-E). Individual methylcellulose colonies were analyzed for EGFP expression by flow cytometry or inverted fluorescence microscopy, and for proviral integration by PCR. The results obtained for the rhesus monkey BM cell populations are summarized in Table 2 . None of the total mocktransduced GM-CFU or BFU-E analyzed by FACS displayed EGFP expression whereas 23% of the GM-CFU and 36% of the BFU-E recovered from the total EGFP-transduced rhesus monkey cell populations revealed a bright green fluorescence signal. All of the GM-CFU and 86% of the BFU-E derived from the CD34 + EGFP-positive selected fraction were clearly expressing EGFP in contrast to those derived from the CD34 + EGFP-negative fraction in which 7% EGFP + colonies were detected (Table 2 ). EGFP expression in clonogenic progenitor cells was further visualized by inverted fluorescence microscopy. Examples of an EGFP-positive GM-CFU and BFU-E derived from the human CD34 + EGFP-positive cell population are shown in Figure 2 . Proviral integration was examined by PCR using EGFP-specific primers, similarly as described 20 in individually isolated methylcellulose colonies. The accumulated results showed that 21 out of 60 colonies (6/29 CFU-GM and 15/31 BFU-E) derived from the total EGFPtransduced population contained EGFP-specific sequences, as compared to none of the mock-transduced and the sorted EGFP − colonies and all of the sorted EGFP + colonies analyzed ( Table 2 ), indicating that EGFP expression correlated well with the presence of the provirus. Neither cloning efficiency nor the size of individual colonies were significantly different between progenitors derived from mock-transduced BM, EGFP-transduced BM or sorted EGFP − or EGFP + subsets (data not shown). These data demonstrate that EGFP expression can be used to enrich for retrovirally transduced human and rhesus monkey hematopoietic progenitor cells, did not affect the growth of clonogenic progenitors and remained stable during both granulocyte/macrophage and erythroid colony formation. 
EGFP expression in immature CD34
+ subsets
Differential expression of the cell surface antigens HLA-DR and CD38 has been used before to discriminate between immature multipotent progenitors and the more mature lineage-committed progenitors in the CD34 + cell population of rhesus monkey and human hematopoietic cells, 23, 24, 34, 35 respectively. To examine the transduction efficiency in subsets identified by these phenotypic markers, EGFP expression was compared by four-color flow cytometric analysis with the expression of the CD34 and HLA-DR (rhesus monkey) or CD34 and CD38 (human) antigens. The total viable and transduced cell population is represented with a transduction efficiency of 25% (Rh4 experiment of Table 1 and Table 3 ). The results of three independent experiments are summarized in Table 3 . The total cell population was divided into four fractions on the basis of CD34 and HLA-DR expression (Figure 3a) , with a significant number of the cells still retaining the CD34 marker ( (Figure 4 , Table 3 ).
EGFP expression in mobilized CD34
+ peripheral blood cells
To examine gene transfer in mobilized peripheral blood cells, a rhesus monkey was treated with FL and G-CSF for 14 consecutive days and CD34 + PB cells, isolated on day 8 and 15 of treatment, were transduced with the MFG-EGFP retroviral vector. In primates, subcutaneous administration of FL mobilizes hematopoietic progenitors into the peripheral blood which is synergistically enhanced with G-CSF. 36 As is shown in Figure 5 , approximately 29% of day 8 and 38% of day 15 PB cells displayed EGFP expression. In a similar experiment, in which a rhesus monkey was treated with FL and G-CSF for 7 consecutive days, 17% of the CD34 + PB cells isolated on day 8 of treatment displayed EGFP expression. Interestingly, approximately у89% of the transduced BM cells (у96% in the EGFP + subset) still retained the CD34 bright phenotype after the 4 days of the retroviral transduction procedure ( Figure 5 ), among which, similar to the BM experiments, EGFP + progenitor cells with in vitro granulocyte/macrophage colony forming ability were present with a transduction frequency similar as the total cell population (results not shown).
Discussion
Recently, the utility of EGFP as a retrovirally encoded reporter molecule for the detection and selection of transduced immature murine hematopoietic progenitor cells and human CD34 + cells derived from cord blood or apheresis products has been explored. [19] [20] [21] These reports suggested the strong potential of EGFP as a selectable marker for identification and tracking of transduced hematopoietic cells in vitro and in vivo, although the application and stability of EGFP expression during longterm repopulating assays has not been reported yet. As a prelude to initiate long-term repopulating assays in primates, we extended our earlier transduction studies with the MFG-EGFP retroviral vector on murine BM cells to hematopoietic progenitor cells derived from BM (human, rhesus monkey) and mobilized PB (rhesus monkey).
Initially, we focused on a EGFP-transduced human myelog- enous leukemia cell line (KG1A) to examine the stability and selectability of EGFP expression. Upon transduction with aMFG-EGFP-derived retrovirus, EGFP expression was readily detectable in the KG1A cells. Transduced KG1A cells could be selected for on the basis of EGFP and CD34 expression up to over 95% purity, suggesting the possibility of using EGFP as a selectable marker for immature hematopoietic cells. This was further demonstrated by selection of both rhesus monkey and human CD34 + EGFP-negative and CD34 + EGFP-positive BM cells to high levels of purity (у87%). The enrichment for EGFP-negative and EGFP-positive erythroid and myeloid clonogenic progenitors in these selected cell populations, respectively, was further demonstrated by flow cytometry, inverted fluorescence microscopy and PCR analysis. Four-color flow cytometry using antibodies specific for CD34 and HLA-DR (rhesus monkey) or CD38 (human) revealed EGFP expression in viable BM cells reported to contain immature multipotent progenitor cells ( + PB cells mobilized with FL and G-CSF were transduced to high efficiency with the MFG-EGFP retroviral vector. This is particularly relevant in view of the rapid repopulation capacity of the PB cells 37 and the option to transduce large numbers of CD34 + cells, thereby possibly increasing the probability of transducing cells with the capacity of sustained hematopoietic reconstitution. Since it is unlikely that all CD34
+ cells with an immature phenotype after transduction still represent immature cells, the repopulation capacity of the transduced needs to be directly assessed in transplantation experiments. In a recent study performed on human umbilical cord blood CD34 + cells, we observed similar high transduction of phenotypically immature CD34 + CD38 − cells, primitive cobble-stone area forming cells (week 5 type CAFC) and cells that could reconstitute multilineage human hemopoiesis in NOD/SCID mice. 22 Those results demonstrate that identification of EGFP-expressing CD34 subsets provide a useful assay to rapidly identify optimal parameters, such as in vivo priming of stem cells and in vitro stimulation with cytokines which can then be used in preclinical transplantation studies to examine the repopulation ability of transduced cells and the contribution of transduced cells to initial regeneration and long-term engraftment of individual blood cell lineages.
Recent reports suggest that a part of the immature cells in human and rhesus monkey BM may be found in the CD34-negative subset, 38 which might indicate that efforts aimed at transduction of repopulating stem cells should not be exclusively focused on the CD34 + cells. However, the significance of CD34
− rhesus monkey stem cells remains uncertain, since results from transplantation studies with such cells have not yet been reported. In addition, it is doubtful that all CD34 − stem cell candidates identified in rhesus monkey BM were truly CD34-negative, since these cells might express forms of CD34 on which the carbohydrate structures recognized by the 12.8 and QBEND/10 anti-CD34 antibodies used 38 to identify these cells, are absent. 39 Since the vast majority of CD34-negative cells in BM are not stem cells, it will in any case be necessary to develop markers to identify and positively select cells with repopulating ability from the CD34 − population before comparative studies aimed at retroviral transduction of putative CD34
− cells with in vivo repopulating ability and their CD34
+ counterparts can be initiated. The high level of EGFP expression did not notably influence the outgrowth and differentiation potential of rhesus monkey and human erythroid and granulocyte/macrophage progenitors in methylcellulose cultures. In addition, cell growth of EGFP-transduced (50% EGFP + ) KG1A cells was not inhibited relative to mock-transduced cells for at least 16 cell divisions. It is of interest that transgenic mice which continuously expressed EGFP in all tissue cells (with the notable exception of hair and red blood cells), were normal and healthy. 40 These results demonstrate that EGFP expression is non-toxic. Foreign proteins introduced into a mammalian organism and also homologous recombinant proteins might potentially induce antibody formation and/or elicit a cytotoxic T lymphocyte response, leading to elimination of transduced cells. This would then limit the use of EGFP and other marker proteins beyond the irradiated, immunosuppressed recipient, in which tolerance induction is the general rule. The potential risk of immunogenicity by no means distracts from the versatile use of EGFP to develop efficient gene transfer protocols in model systems and trials, a purpose for which this marker might have several advantages compared to other selectable markers, such as MDR1, LNGFR, CD24, or HSA. First of all, due to its intrinsic fluorescence properties, EGFP expression can be directly visualized in viable cells by flow cytometry and fluorescence microscopy without the need for time-consuming staining procedures, which facilitates identification and tracking of viable retrovirally transduced cells. Second, the fluorescence intensity level of EGFP in transduced primary murine 19, 20 and primate hematopoietic cells (Refs 21, 22 and this report) is high relative to antibody-visualized cell surface markers as is clearly demonstrated in a direct comparison between EGFP-and CD24-transduced murine BM cells, 19 which facilitates the selection and purification of suitable numbers of transduced cells for transplantation in mice and nonhuman primates. Such studies are essential to gain insight into the intrinsic functional properties of the transduced cells, the stability of EGFP expression in vivo over prolonged periods of time and its immunogenicity. Third, the lack of endogenous expression levels and specific function for EGFP in mammalian cell types favors its application over functional molecules such as MDR1 and CD24 which, for example, are already expressed at low levels in human hematopoietic cells, 4, 41 and which, in the case of MDR-1, might alter cellular survival, proliferation and differentiation when overexpressed in stem cells. 42 Fourth, GFP may serve as a fusion partner for intracellular expression of biologically relevant proteins, as for example, has recently been demonstrated for the Fanconi anemia complementation group A gene product, 43 or their dominant negative counterparts with the potential of targeting chimeric proteins to specific cell organelles and studying their biological effects in purified primary cell populations.
